Biosimulation Market by Offering, Delivery Model, End-User, Application

List of Tables

[197 Pages Report] The Biosimulation Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.40 billion in 2024, at a CAGR 14.55% to reach USD 9.87 billion by 2030.

Biosimulation combines mathematics, biology, and computer programming to create simulations to test hypotheses, predict outcomes, and explore new possibilities in biotechnology. By simulating biological phenomena such as gene expression, metabolism, and cell growth, biosimulation helps researchers better understand the complexities of life and develop new products for healthcare. The increasing development of new drugs and medicines and the growing government focus on integrating digitalized technologies in pharmaceutical and biopharmaceutical sectors are elevating the need for biosimulation systems. However, the high cost associated with developing biosimulation software hampers market growth. The growing integration of computer-aided design (CAD) and virtual reality (VR) technologies, as well as advancements in artificial intelligence (AI) and machine learning (ML) for the development of new biosimulation software, is expected to expand the scope of the biosimulation market.

KEY MARKET STATISTICS
Base Year [2023]	USD 3.81 billion
Estimated Year [2024]	USD 4.40 billion
Forecast Year [2030]	USD 9.87 billion
CAGR (%)	14.55%

Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization

Contract services are provided by specialized companies and research organizations that offer biosimulation expertise to clients, which assist with model development, simulation studies, data analysis, and interpretation. In-house services are biosimulation services conducted within an organization and research institution. Molecular modeling & simulation software focuses on simulating and modeling the behavior of molecules, such as proteins, nucleic acids, and small molecules. It is used to study molecular interactions and conformational changes and predict properties such as binding affinity. PBPK modeling & simulation software is designed to simulate the distribution, absorption, metabolism, and excretion of drugs and chemicals in the body. PK/PD, modeling & simulation software, affects drugs' pharmacokinetic and pharmacodynamic properties, helps predict drug concentrations and exposure-response relationships, and optimizes dosing regimens. Toxicity prediction software focuses on predicting the potential toxicity of chemical compounds. It uses computational models to assess the safety and potential risks of exposure to specific chemicals or drugs. Trial design software helps in the design and optimization of clinical trials and also simulates different trial scenarios, evaluates statistical power, and optimizes sample sizes to improve the efficiency and validity of clinical studies.

Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users

In the biosimulation ownership model, users purchase the software and service outright, giving them full control over the software and its usage. In the biosimulation ownership model, users purchase a perpetual license for the software, granting them the right to use it indefinitely. Subscription models involve users paying a recurring fee to access and use the software or services. With this model, users usually do not own the software but have ongoing access to the latest versions and updates.

End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies

Contract research organizations (CROs) often utilize biosimulation to support their clients' drug discovery and development processes and offer services such as molecular modeling, PK/PD modeling, toxicity prediction, and trial design using biosimulation techniques. Pharmaceutical & biotechnology companies extensively employ biosimulation throughout the drug development pipeline. Regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), play a crucial role in evaluating drug safety and effectiveness before being approved for market release. Regulatory authorities use biosimulation to assess the risk-benefit profile of drugs, optimize study designs, and make informed decisions during the drug approval process. Research institutes, including academic institutions and government organizations, employ biosimulation to advance scientific knowledge and conduct advanced research. Researchers utilize biosimulation tools and techniques to model and simulate complex biological systems, explore hypotheses, and gain insights into fundamental biological processes.

Application: Increasing application of biosimulation for drug development

Biosimulation plays a vital role in drug development by providing insights and predictions related to drug pharmacokinetic (PK) and pharmacodynamic (PD) properties, assisting in optimizing dosing regimens, predicting drug concentrations in target tissues, and assessing drug candidates' potential efficacy and safety. Biosimulation techniques, such as PBPK and PK/PD modeling, aid in making informed decisions during drug development. Biosimulation supports the design and optimization of clinical trials and enables the prediction and evaluation of drugs and chemical compounds' absorption, distribution, metabolism, excretion, and toxicity properties. Biosimulation helps identify potential ADME/Tox issues early in the drug development process, reducing the need for extensive animal testing and providing insights into potential risks. PK/PD modeling and simulation assist in predicting the relationship between drug exposure and response. Biosimulation supports lead identification & optimization by employing molecular modeling and simulation techniques. It aids in screening and evaluating potential drug candidates, predicting their binding affinity to target molecules, and optimizing their chemical structures for improved potency and selectivity. Biosimulation techniques aid in the identification and validation of potential drug targets. By modeling and simulating the interactions between drug molecules and target proteins, biosimulation helps evaluate the feasibility and potential effectiveness of targeting specific proteins.

Regional Insights

The Americas region showcases a highly developing landscape for the biosimulation market owing to the presence of major established players in the United States and their ongoing efforts to advance biosimulation software. Well-established regulatory authorities such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada to ensure the safety and efficiency of drug development and clinical trials are benefiting the market growth across the Americas, Europe, and Asia-Pacific. Considering the EMEA region, the increasing investment in drug development and clinical trials across UK, Germany, and France is expanding the adoption of biosimulation software & services. The increasing number of chronic diseases across Asia-Pacific encourages government and regulatory authorities to expand their funding activities for drug development which is expected to create a platform for developing the biosimulation market. The presence of various initiatives such as Australia's Drug Discovery Initiative and Medical Research Commercialisation Initiative that aims at pharmaceutical research and development (R&D) activities is expanding the usage of biosimulation in Asia-pacific.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Biosimulation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biosimulation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Applied BioMath, LLC, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Compugen Ltd., Crystal Pharmatech Co., Ltd., Dassault Systemes SE, Genedata AG, Immunetrics Inc, In Silico Biosciences, Inc., INOSIM Software GmbH, Instem PLC, Laboratory Corporation of America Holdings, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Rosa & Co LLC, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life., VIRTUALMAN, and Yokogawa Electric Corporation.

Market Segmentation & Coverage

This research report categorizes the Biosimulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

Offering
- Services
  - Contract Services
  - In-House Services

Software
- Molecular Modeling & Simulation Software
- PBPK Modeling & Simulation Software
- PK/PD Modeling & Simulation Software
- Toxicity Prediction Software
- Trial Design Software

Delivery Model
- Ownership Models
- Subscription Models

End-User
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
- Regulatory Authorities
- Research Institutes

Application
- Drug Development
  - Clinical Trials
  - Preclinical Testing
    - ADME/Tox
    - PK/PD
- Drug Discovery
  - Lead Identification & Optimization
  - Target Identification & Validation
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Biosimulation Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biosimulation Market?

3. What are the technology trends and regulatory frameworks in the Biosimulation Market?

4. What is the market share of the leading vendors in the Biosimulation Market?

5. Which modes and strategic moves are suitable for entering the Biosimulation Market?

Product Code: MRR-2D64BA93AB17

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing emphasis on research of personalized medicine
  - 5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
- 5.1.2. Restraints
  - 5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
  - 5.1.3.2. Rising investments for drug developments and drug testings
- 5.1.4. Challenges
  - 5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
5.2. Market Segmentation Analysis
- 5.2.1. Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
- 5.2.2. Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users
- 5.2.3. End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
- 5.2.4. Application: Increasing application of biosimulation for drug development
5.3. Market Trend Analysis
- 5.3.1. Significant investments in drug development and collaborative activities to expand the usage of biosimulation in the Americas
- 5.3.2. Government initiatives to encourage the adoption of innovative technologies in pharmaceutical research in the APAC
- 5.3.3. Increasing clinical trials and drug development activities expanding the scope of biosimulation in the EMEA region
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis

6. Biosimulation Market, by Offering

6.1. Introduction
6.2. Services
6.3. Software

7. Biosimulation Market, by Delivery Model

7.1. Introduction
7.2. Ownership Models
7.3. Subscription Models

8. Biosimulation Market, by End-User

8.1. Introduction
8.2. Contract Research Organizations
8.3. Pharmaceutical & Biotechnology Companies
8.4. Regulatory Authorities
8.5. Research Institutes

9. Biosimulation Market, by Application

9.1. Introduction
9.2. Drug Development
9.3. Drug Discovery

10. Americas Biosimulation Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Biosimulation Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Biosimulation Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Certara and DNDi Partnering to Fast-track Data Submissions and Accelerate Drug Approvals for Neglected Patients
- 13.3.2. Certara Launches Version 8.4 of Phoenix Biosimulation Software for Drug Development
- 13.3.3. Certara Amplifies CODEX Platform Capabilities with AI for Drug Discovery
- 13.3.4. Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
- 13.3.5. Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
- 13.3.6. Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
- 13.3.7. Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool
- 13.3.8. Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
- 13.3.9. Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
- 13.3.10. Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma
- 13.3.11. Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease
- 13.3.12. GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
- 13.3.13. Cadence Expands into Molecular Simulation with Acquisition of OpenEye Scientific, a Pioneering Leader in Computational Molecular Design
- 13.3.14. Resolution Medical Acquires LifeTec Group
- 13.3.15. Colorcon Ventures Invests in AI-Driven Bio-simulation Company VeriSIM Life

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio